| Literature DB >> 27239103 |
Marius Schild1, Gerrit Eichner2, Thomas Beiter3, Martina Zügel4, Ilke Krumholz-Wagner1, Jens Hudemann3, Christian Pilat1, Karsten Krüger1, Andreas M Niess3, Jürgen M Steinacker4, Frank C Mooren1.
Abstract
Acute physical exercise and repeated exercise stimuli affect whole-body metabolic and immunologic homeostasis. The aim of this study was to determine plasma protein profiles of trained (EET, n = 19) and untrained (SED, n = 17) individuals at rest and in response to an acute bout of endurance exercise. Participants completed a bicycle exercise test at an intensity corresponding to 80% of their VO2max. Plasma samples were taken before, directly after, and three hours after exercise and analyzed using multiplex immunoassays. Seventy-eight plasma variables were included in the final analysis. Twenty-nine variables displayed significant acute exercise effects in both groups. Seven proteins differed between groups, without being affected by acute exercise. Among these A2Macro and IL-5 were higher in EET individuals while leptin showed elevated levels in SED individuals. Fifteen variables revealed group and time differences with elevated levels for IL-3, IL-7, IL-10, and TNFR2 in EET individuals. An interaction effect could be observed for nine variables including IL-6, MMP-2, MMP-3, and muscle damage markers. The proteins that differ between groups indicate a long-term exercise effect on plasma protein concentrations. These findings might be of importance in the development of exercise-based strategies in the prevention and therapy of chronic metabolic and inflammatory diseases and for training monitoring.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27239103 PMCID: PMC4867072 DOI: 10.1155/2016/4851935
Source DB: PubMed Journal: Mediators Inflamm ISSN: 0962-9351 Impact factor: 4.711
The anthropometric data and performance results of the entrance examination and endurance exercise of EET and SED individuals. Shown are mean ± SD and in parentheses the 1. quartile, median, and the 3. quartile. p < 0.001 indicates significant differences between endurance-exercise-trained (EET) athletes and untrained/sedentary (SED) individuals.
| EET ( | SED ( | |
|---|---|---|
|
| ||
| Age (years) | 25 ± 2.9 (24, 26, 27) | 24 ± 3.5 (21, 22, 28) |
| Weight (kg) | 73.9 ± 8.3 (70, 73, 77) | 77.9 ± 12.4 (69, 76, 84) |
| Height (kg) | 180.4 ± 6.5 (174, 181, 186) | 177.9 ± 5.5 (174, 176, 180) |
| BMI | 22.5 ± 1.6 (21, 23, 24) | 24.7 ± 4.1 (22, 24, 27) |
|
| ||
| VO2max [mL/min/kg] | 65.6 ± 6.7 (61, 66, 71) | 40.5 ± 6.1 (39, 41, 45) |
| Maximum performance [watts] | 339.5 ± 45.9 (307, 333, 387) | 206.4 ± 32.4 (202, 217, 225) |
| Maximum performance [watts/kg] | 4.6 ± 0.6 (4.0, 4.5, 5.0) | 2.7 ± 0.5 (2.5, 2.8, 3.1) |
| Maximum lactate [mmol/L] | 12 ± 2.0 (11, 12, 13) | 10.4 ± 3.2 (7, 10, 13) |
| Maximum HR [beats/min] | 188.9 ± 10.0 (183, 191, 196) | 188.7 ± 9.3 (182, 188, 197) |
| Performance at IAT [watts/kg] | 2.9 ± 0.5 (2.5, 2.7, 3.3) | 1.4 ± 0.4 (1.2, 1.6, 1.7) |
| Lactate at IAT [mmol/L] | 2.4 ± 0.4 (2.0, 2.4, 2.7) | 2.5 ± 0.5 (2.1, 2.5, 2.7) |
|
| ||
| Performance at 80% VO2max [watts] | 254.1 ± 45.4 (227, 240, 280) | 156.4 ± 32.0 (150, 167, 175) |
| Average lactate [mmol/L] | 6.7 ± 3.1 (4.1, 5.9, 8.9) | 6.1 ± 2.9 (3.8, 4.9, 7.1) |
| HR at end [beats/min] | 178.8 ± 12.4 (168, 178, 189) | 177.4 ± 8.2 (170, 175, 184) |
BMI = Body Mass Index; HR = heart rate; IAT = individual anaerobic threshold; VO2max = maximal oxygen consumption.
Figure 1Experimental setup of the study enrollment.
Leukocytes, neutrophils, lymphocytes, and monocytes counts are shown in cells/μL. Displayed is the median with the 1. and 3. quartile in parentheses. p < 0.01 and p < 0.001 indicate significant differences from baseline.
| Variable | Median (1. quartile; 3. quartile) | ||
|---|---|---|---|
| Pre | Post | 3 h | |
| Leukocytes | 5080 (4030; 5755) | 6209 (5518; 7645) | 8998 (7496; 10565) |
| Neutrophils | 2614 (2164; 3343) | 3556 (2954; 4606) | 6427 (5448; 8472) |
| Lymphocytes | 1672 (1397; 1850) | 2097 (1810; 2456) | 1561 (1350; 1773) |
| Monocytes | 378 (299; 439) | 478 (375; 602) | 501 (397; 610) |
Figure 2Hierarchical cluster analysis of significant variables with (a) main effect time point and (b) group, group and time, and interaction effect at each time point between EET and SED individuals using Ward's method. Differences are represented by the computed RTEs. Red colour representing higher and green lower RTEs. EET: endurance-exercise-trained; SED: untrained/sedentary.
Plasma variables of Tables 3(c) and 3(d) with significant differences between EET and SED individuals at baseline (pre). Displayed are the relative treatment effects (RTEs) and their corresponding 95% confidence intervals (CI). $ p < 0.05 and $$ p < 0.01 indicate significant differences between groups. EET: endurance-exercise-trained; SED: untrained/sedentary.
| Variable | Group | RTE (CI) pre |
|---|---|---|
| AAT | EET | 0.55 (0.45; 0.65) |
| SED | 0.35 (0.27; 0.43)$ | |
|
| ||
| B2M | EET | 0.48 (0.39; 0.57) |
| SED | 0.26 (0.2; 0.34)$ | |
|
| ||
| CK-MB | EET | 0.54 (0.45; 0.62) |
| SED | 0.27 (0.21; 0.35)$$ | |
|
| ||
| GH | EET | 0.37 (0.31; 0.43) |
| SED | 0.22 (0.17; 0.29)$ | |
|
| ||
| IL-3 | EET | 0.63 (0.54; 0.71) |
| SED | 0.34 (0.26; 0.44)$$ | |
|
| ||
| IL-7 | EET | 0.59 (0.5; 0.67) |
| SED | 0.36 (0.27; 0.47)$ | |
|
| ||
| MCP-1 | EET | 0.52 (0.42; 0.61) |
| SED | 0.28 (0.21; 0.37)$ | |
|
| ||
| TNFR2 | EET | 0.54 (0.45; 0.63) |
| SED | 0.32 (0.24; 0.42)$ | |
|
| ||
| VCAM-1 | EET | 0.53 (0.44; 0.63) |
| SED$ | 0.33 (0.26; 0.42)$ | |
AAT = alpha-1-antitrypsin; B2M = Beta 2 Microglobulin; GH = growth hormone; IL-3 = interleukin-3; IL-7 = interleukin-7; IL-8 = interleukin-8; IL-10 = interleukin-10; IL-13 = interleukin-13; MCP-1 = monocyte chemotactic protein-1; TNF-α = tumor necrosis factor-alpha; TNFR2 = tumor necrosis factor receptor 2; VCAM-1 = Vascular Cell Adhesion Molecule-1.
| Variable | RTE (CI) | ||
|---|---|---|---|
| Pre | Post | 3 h | |
| Adiponectin | 0.47 (0.45; 0.5) | 0.51 (0.5; 0.53) | 0.51 (0.49; 0.53) |
| AFP | 0.49 (0.46; 0.52) | 0.56 (0.52; 0.6) | 0.45 (0.42; 0.48) |
| Apo H | 0.46 (0.43; 0.50) | 0.50 (0.47; 0.54) | 0.53 (0.50; 0.56) |
| BDNF | 0.44 (0.41; 0.47) | 0.57 (0.55; 0.6) | 0.49 (0.46; 0.53) |
| EN-RAGE | 0.25 (0.21; 0.30) | 0.72 (0.67; 0.76) | 0.53 (0.49; 0.57) |
| Eotaxin 1 | 0.48 (0.44; 0.52) | 0.56 (0.51; 0.61) | 0.46 (0.40; 0.51) |
| EGF | 0.46 (0.42; 0.49) | 0.53 (0.5; 0.56) | 0.51 (0.48; 0.54) |
| ENA-78 | 0.44 (0.42; 0.47) | 0.56 (0.53; 0.59) | 0.50 (0.47; 0.52) |
| G-CSF | 0.40 (0.35; 0.46) | 0.57 (0.54; 0.6) | 0.53 (0.49; 0.57) |
| ICAM-1 | 0.46 (0.42; 0.49) | 0.53 (0.5; 0.57) | 0.51 (0.48; 0.54) |
| IL-1 | 0.39 (0.34; 0.46) | 0.64 (0.57; 0.69) | 0.47 (0.41; 0.54) |
| IL-1ra | 0.42 (0.37; 0.47) | 0.52 (0.46; 0.59) | 0.56 (0.50; 0.61) |
| IL-16 | 0.28 (0.25; 0.32) | 0.67 (0.64; 0.70) | 0.55 (0.53; 0.57) |
| IL-18 | 0.46 (0.43; 0.49) | 0.52 (0.49; 0.56) | 0.51 (0.48; 0.55) |
| MIP-1 | 0.45 (0.41; 0.48) | 0.50 (0.47; 0.53) | 0.56 (0.52; 0.60) |
| MMP-9 | 0.27 (0.23; 0.31) | 0.58 (0.53; 0.61) | 0.66 (0.61; 0.70) |
| MPO | 0.34 (0.29; 0.39) | 0.67 (0.61; 0.71) | 0.50 (0.45; 0.55) |
| PAI-1 | 0.46 (0.43; 0.49) | 0.54 (0.51; 0.57) | 0.50 (0.46; 0.54) |
| PAPP-A | 0.41 (0.35; 0.48) | 0.60 (0.55; 0.66) | 0.49 (0.43; 0.54) |
| PAP | 0.56 (0.53; 0.6) | 0.58 (0.52; 0.63) | 0.36 (0.31; 0.41) |
| SGOT | 0.45 (0.40; 0.51) | 0.46 (0.41; 0.52) | 0.58 (0.53; 0.63) |
| SCF | 0.45 (0.42; 0.48) | 0.54 (0.51; 0.58) | 0.51 (0.48; 0.55) |
| RANTES | 0.44 (0.41; 0.47) | 0.57 (0.54; 0.59) | 0.49 (0.47; 0.52) |
| Thrombospondin 1 | 0.42 (0.39; 0.46) | 0.59 (0.56; 0.62) | 0.49 (0.45; 0.52) |
| TSH | 0.53 (0.48; 0.57) | 0.58 (0.54; 0.63) | 0.39 (0.35; 0.43) |
| TBG | 0.46 (0.42; 0.50) | 0.50 (0.47; 0.53) | 0.54 (0.51; 0.58) |
| TIMP-1 | 0.43 (0.39; 0.48) | 0.56 (0.51; 0.61) | 0.51 (0.46; 0.55) |
| VEGF | 0.40 (0.37; 0.44) | 0.53 (0.5; 0.57) | 0.57 (0.52; 0.61) |
| vWF | 0.32 (0.26; 0.40) | 0.60 (0.54; 0.66) | 0.58 (0.5; 0.64) |
AFP = Alpha Fetoprotein; Apo H = Apolipoprotein H; BDNF = brain-derived neurotrophic factor; EN-RAGE: extracellular newly identified receptor for advanced glycation end-products binding protein; EGF = Epidermal Growth Factor; ENA-78 = epithelial-derived neutrophil-activating protein 78; G-CSF = granulocyte-colony stimulating factor; ICAM-1 = Intercellular Adhesion Molecule 1; IL-1β = interleukin-1 beta; IL-1ra = interleukin-1 receptor antagonist; IL-16 = interleukin-16; IL-18 = interleukin-18; MIP-1β = macrophage inflammatory protein-1 beta; MMP-9 = matrix metalloproteinase-9; MPO = myeloperoxidase; PAI-1 = Plasminogen Activator Inhibitor-1; PAPP-A = Pregnancy Associated Plasma Protein-A; PAP = Prostatic Acid Phosphatase; RANTES = regulated upon activation normal T-cell expressed and secreted; SGOT = Serum Glutamic Oxaloacetic Transaminase; SCF = stem cell factor; TSH = Thyroid Stimulating Hormone; TBG = Thyroxine Binding Globulin; TIMP-1 = tissue inhibitor of metalloproteinase-1; VEGF = vascular endothelial growth factor; vWF = von Willebrand factor.
| Variable | RTE (CI) |
|---|---|
| A2Macro$$ | 0.71 (0.60; 0.82) |
| Apo A-I$ | 0.71 (0.60; 0.81) |
| Apo C-III$ | 0.32 (0.21; 0.43) |
| IL-5$$ | 0.77 (0.67; 0.87) |
| Leptin$$$ | 0.09 (0.03; 0.14) |
| MDC$ | 0.32 (0.22; 0.43) |
| SAP$$$ | 0.22 (0.13; 0.31) |
A2Macro = alpha-2-macroglobulin; APO A-I = Apolipoprotein A-I; Apo C-III = Apolipoprotein C-III; IL-5 = interleukin-5; MDC = macrophage-derived chemokine; SAP = serum amyloid P-component.
| Variable | Group | RTE (CI) | ||
|---|---|---|---|---|
| Pre | Post | 3 h | ||
| AAT | EET | 0.55 (0.45; 0.65) | 0.59 (0.48; 0.68) | 0.66 (0.56; 0.74) |
| SED$$ | 0.35 (0.27; 0.43) | 0.35 (0.25; 0.47) | 0.46 (0.38; 0.55) | |
|
| ||||
| CA-125 | EET | 0.48 (0.38; 0.59) | 0.74 (0.63; 0.81) | 0.52 (0.42; 0.61) |
| SED$ | 0.38 (0.29; 0.48) | 0.52 (0.42; 0.62) | 0.33 (0.25; 0.44) | |
|
| ||||
| CD40 | EET | 0.50 (0.4; 0.6) | 0.68 (0.59; 0.76) | 0.59 (0.49; 0.68) |
| SED$ | 0.38 (0.29; 0.49) | 0.44 (0.33; 0.55) | 0.38 (0.28; 0.49) | |
|
| ||||
| GH | EET | 0.37 (0.31; 0.43) | 0.85 (0.81; 0.87) | 0.45 (0.4; 0.51) |
| SED$$ | 0.22 (0.17; 0.29) | 0.79 (0.74; 0.83) | 0.29 (0.22; 0.39) | |
|
| ||||
| Insulin | EET | 0.57 (0.48; 0.65) | 0.30 (0.23; 0.39) | 0.42 (0.31; 0.53) |
| SED$ | 0.71 (0.59; 0.8) | 0.46 (0.34; 0.58) | 0.57 (0.45; 0.68) | |
|
| ||||
| IL-3 | EET | 0.63 (0.54; 0.71) | 0.62 (0.53; 0.7) | 0.68 (0.59; 0.75) |
| SED$$$ | 0.34 (0.26; 0.44) | 0.31 (0.23; 0.4) | 0.37 (0.29; 0.46) | |
|
| ||||
| IL-7 | EET | 0.59 (0.5; 0.67) | 0.62 (0.53; 0.69) | 0.66 (0.57; 0.74) |
| SED$$ | 0.36 (0.27; 0.47) | 0.34 (0.26; 0.44) | 0.39 (0.3; 0.48) | |
|
| ||||
| IL-8 | EET | 0.48 (0.39; 0.58) | 0.73 (0.66; 0.79) | 0.56 (0.46; 0.64) |
| SED$$ | 0.33 (0.23; 0.45) | 0.53 (0.41; 0.63) | 0.34 (0.26; 0.43) | |
|
| ||||
| IL-10 | EET | 0.37 (0.29; 0.46) | 0.81 (0.74; 0.86) | 0.56 (0.46; 0.65) |
| SED$$ | 0.32 (0.24; 0.41) | 0.56 (0.45; 0.65) | 0.36 (0.27; 0.46) | |
|
| ||||
| IL-13 | EET | 0.60 (0.51; 0.69) | 0.55 (0.46; 0.64) | 0.63 (0.53; 0.71) |
| SED$ | 0.39 (0.3; 0.49) | 0.38 (0.29; 0.48) | 0.42 (0.32; 0.52) | |
|
| ||||
| MCP-1 | EET | 0.52 (0.42; 0.61) | 0.77 (0.69; 0.83) | 0.48 (0.4; 0.57) |
| SED$$ | 0.28 (0.21; 0.37) | 0.57 (0.44; 0.69) | 0.35 (0.25; 0.47) | |
|
| ||||
| Myoglobin | EET | 0.27 (0.21; 0.35) | 0.58 (0.51; 0.64) | 0.79 (0.74; 0.82) |
| SED$ | 0.17 (0.14; 0.23) | 0.41 (0.33; 0.50) | 0.76 (0.66; 0.83) | |
|
| ||||
| TNF- | EET | 0.56 (0.47; 0.64) | 0.64 (0.55; 0.71) | 0.56 (0.47; 0.65) |
| SED$ | 0.40 (0.3; 0.51) | 0.44 (0.35; 0.53) | 0.38 (0.29; 0.48) | |
|
| ||||
| TNFR2 | EET | 0.54 (0.45; 0.63) | 0.74 (0.65; 0.8) | 0.60 (0.52; 0.68) |
| SED$$$ | 0.32 (0.24; 0.42) | 0.38 (0.31; 0.47) | 0.36 (0.28; 0.45) | |
|
| ||||
| VCAM-1 | EET | 0.53 (0.44; 0.63) | 0.66 (0.57; 0.73) | 0.60 (0.51; 0.69) |
| SED$ | 0.33 (0.26; 0.42) | 0.41 (0.32; 0.51) | 0.43 (0.34; 0.53) | |
AAT = alpha-1-antitrypsin; CA-125 = Cancer Antigen 125; CD40 = CD 40 antigen; GH = growth hormone; IL-3 = interleukin-3; IL-7 = interleukin-7; IL-8 = interleukin-8; IL-10 = interleukin-10; IL-13 = interleukin-13; MCP-1 = monocyte chemotactic protein-1; TNF-α = tumor necrosis factor-alpha; TNFR2 = tumor necrosis factor receptor 2; VCAM-1 = Vascular Cell Adhesion Molecule-1.
| Variable | Group | RTE (CI) | ||
|---|---|---|---|---|
| Pre | Post | 3 h | ||
| B2M | EET | 0.48 (0.39; 0.57) | 0.82 (0.75; 0.86) | 0.60 (0.51; 0.69) |
| SED§/$$$ | 0.26 (0.20; 0.34)$ | 0.42 (0.34; 0.52) | 0.37 (0.29; 0.46)$ | |
|
| ||||
| CA-19-9 | EET | 0.44 (0.34; 0.55) | 0.52 (0.42; 0.62) | 0.54 (0.45; 0.63) |
| SED§ | 0.52 (0.41; 0.63) | 0.52 (0.42; 0.62) | 0.46 (0.36; 0.57) | |
|
| ||||
| CEA | EET | 0.47 (0.38; 0.57) | 0.67 (0.58; 0.74) | 0.48 (0.38; 0.58) |
| SED§ | 0.42 (0.32; 0.53) | 0.49 (0.39; 0.6) | 0.45 (0.35; 0.56) | |
|
| ||||
| CK-MB | EET | 0.54 (0.45; 0.62) | 0.69 (0.6; 0.75) | 0.74 (0.69; 0.79) |
| SED§/$$$ | 0.27 (0.21; 0.35)$$ | 0.27 (0.20; 0.36)$$$ | 0.44 (0.35; 0.53) | |
|
| ||||
| FABP, heart | EET | 0.27 (0.2; 0.36) | 0.67 (0.59; 0.73) | 0.68 (0.6; 0.75) |
| SED§ | 0.25 (0.19; 0.34) | 0.44 (0.36; 0.54) | 0.67 (0.54; 0.77) | |
|
| ||||
| IL-6 | EET | 0.26 (0.2; 0.34) | 0.81 (0.74; 0.85) | 0.44 (0.34; 0.54) |
| SED§ | 0.36 (0.26; 0.48) | 0.64 (0.54; 0.73) | 0.50 (0.39; 0.61) | |
|
| ||||
| MMP-2 | EET | 0.52 (0.42; 0.61) | 0.73 (0.65; 0.79) | 0.61 (0.52; 0.69) |
| SED§§/$$ | 0.35 (0.27; 0.43) | 0.38 (0.30; 0.49)$$ | 0.37 (0.29; 0.46)$ | |
|
| ||||
| MMP-3 | EET | 0.39 (0.31; 0.48) | 0.81 (0.73; 0.86) | 0.49 (0.40; 0.58) |
| SED§§ | 0.33 (0.26; 0.41) | 0.57 (0.47; 0.66) | 0.39 (0.3; 0.50) | |
|
| ||||
| PSA-f | EET | 0.52 (0.42; 0.61) | 0.66 (0.55; 0.74) | 0.50 (0.41; 0.59) |
| SED§ | 0.43 (0.34; 0.53) | 0.46 (0.37; 0.56) | 0.40 (0.31; 0.51) | |
B2M = Beta 2 Microglobulin; CA-19-9 = Cancer Antigen 19-9; CEA = Carcinoembryonic Antigen; CK-MB = creatine kinase MB; FABP, heart = fatty acid-binding protein, heart; IL-6 = interleukin-6; MMP-2 = matrix metalloproteinase-2; PSA-f = Prostate Specific Antigen.